Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. | Cell Death Discov | 2024 | 38225241 | PubTator, text mining | PubMed |
| The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma. | Open Med (Wars) | 2024 | 38221934 | PubTator, text mining | PubMed |
| METTL14 contributes to acute lung injury by stabilizing NLRP3 expression in an IGF2BP2-dependent manner. | Cell Death Dis | 2024 | 38218935 | PubTator, text mining | PubMed |
| FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. | Cell Death Dis | 2024 | 38216561 | PubTator, text mining | PubMed |
| Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer. | BMC Genomics | 2024 | 38212708 | PubTator, text mining | PubMed |
| Characterization of m6A methylation modifications in gastric cancer. | Aging (Albany NY) | 2024 | 38206646 | PubTator, text mining | PubMed |
| YTHDF3 modulates the Cbln1 level by recruiting BTG2 and is implicated in the impaired cognition of prenatal hypoxia offspring. | iScience | 2024 | 38205248 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant phenotype of gastric cancer. | BMC Gastroenterol | 2024 | 38200441 | PubTator, text mining | PubMed |
| Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer. | J Immunol | 2024 | 38197667 | PubTator, text mining | PubMed |
| Discovery of a PROTAC degrader for METTL3-METTL14 complex. | Cell Chem Biol | 2024 | 38194973 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications. | Heliyon | 2024 | 38192819 | PubTator, text mining | PubMed |
| TME-Related Biomimetic Strategies Against Cancer. | Int J Nanomedicine | 2024 | 38192633 | PubTator, text mining | PubMed |
| The m6A reader YTHDC2 regulates UVB-induced DNA damage repair and histone modification. | Photochem Photobiol | 2024 | 38190286 | PubTator, text mining | PubMed |
| Mutuality of epigenetic and nanoparticles: two sides of a coin. | Heliyon | 2024 | 38187314 | PubTator, text mining | PubMed |
| Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis. | Neoplasia | 2024 | 38184887 | PubTator, text mining | PubMed |
| CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis. | Mol Cancer | 2024 | 38184608 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. | Mol Cancer | 2024 | 38184597 | PubTator, text mining | PubMed |
| PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. | Cell Death Discov | 2024 | 38182573 | PubTator, text mining | PubMed |
| Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. | Eur J Med Res | 2024 | 38173044 | PubTator, text mining | PubMed |
| WTAP-mediated m6A modification of FRZB triggers the inflammatory response via the Wnt signaling pathway in osteoarthritis. | Exp Mol Med | 2024 | 38172596 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=31